Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001
We report the case of a patient who developed eosinophilic fasciitis, possibly induced by the 3-hydroxy-3-methylglutaryl coenzyme A reductase, simvastatin.
A 66-year-old woman presented with myalgias of the legs and arms associated with muscle weakness and erythrosis of the face 18 months after beginning oral treatment with 20 mg of simvastatin daily for primary hypercholesterolemia. She had no history of atopy, asthma, or chronic disease. She had not traveled out of France for the previous 12 months. Three months after the first symptoms began, she suffered from proximal muscle weakness, peripheral edema, and fasciitis on the flank and forearms. An electromyogram showed signs of myositis. Creatine kinase and lactic acid dehydrogenase levels remained within normal limits, but aldolase levels were elevated (9 U/L; normal, <7.6 U/L), as were eosinophil counts (1.4 × 109/L). Results of a histological examination of a deep cutaneous biopsy specimen were suggestive of eosinophilic fasciitis: the muscular fascia was thick and homogeneous; it contained a diffuse inflammatory infiltrate of lyMPHocytes and eosinophils predominating around blood vessels. Simvastatin treatment was discontinued.
Choquet-Kastylevsky G, Kanitakis J, Dumas V, Descotes J, Faure M, Claudy A. Eosinophilic Fasciitis and Simvastatin. Arch Intern Med. 2001;161(11):1456-1457. doi: